Savanna Capital Corp. Enters Into Definitive

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
207
Savanna Capital Corp. Enters Into Definitive Agreement With Varianz Corp.

TORONTO, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Savanna Capital Corp. (“ Savanna ”), a capital pool company as defined under Policy 2.4 – Capital Pool Companies (the “ CPC Policy ”) of the TSX Venture Exchange (the “ Exchange ”), is pleased to announce that it has entered into a business combination agreement (the “ Agreement ”) with Varianz Corp. (“ Varianz ”), which outlines the terms and conditions pursuant to which Savanna and Varianz agree to effect the combination of their respective businesses and assets by way of a “three-cornered amalgamation” among Savanna, a wholly-owned subsidiary of Savanna (“ Subco ”) and Varianz. 

Subject to regulatory approval, shareholder approval and other conditions set out in the Agreement, Savanna will become the resulting issuer, a medicinal cannabis producer with the name “Varianz Group Corp.” or such other similar name as may be accepted by the relevant regulatory authorities and approved by its board of directors (the “ Resulting Issuer ”).

TRANSACTION SUMMARY

Savanna and Varianz intend to carry out the proposed business combination whereby Savanna will acquire all of the issued and outstanding shares of Varianz by means of a three-cornered amalgamation among Savanna, Varianz and Subco under the provisions of the Ontario Business Corporations Act and related transaction steps as Savanna’s “Qualifying Transaction” pursuant to the CPC Policy (the “ Transaction ”).

Prior to the completion of the business combination contemplated herein, Varianz intends to engage an agent (the “ Agent ’) to assist in the completion of a brokered private placement (the “ Varianz Brokered Offering ”) of subscription receipts of Varianz (each being a “ Brokered Varianz Subscription Receipt ”), the aggregate number and price of which shall be determined by Varianz, Savanna and the Agent acting reasonably. Each Brokered Varianz Subscription Receipt shall entitle its holder to acquire, upon the satisfaction of certain conditions and for no additional consideration or effort on the part of the holder thereof, Varianz securities, which will in turn be exchanged for equivalent securities in the capital of the Resulting Issuer.

Two principal shareholders of Varianz, Ribagorza Investment S.A. and Landsons Investments Corporation (both Panamanian companies), are each expected to own approximately 27% of the common shares of the Resulting Issuer after giving effect to the Transaction, but before the Varianz Brokered Offering or any subsequent financings, and therefore each is expected to become an insider of the Resulting Issuer by virtue of its shareholdings.

If the necessary approvals of the shareholders of Varianz and the TSXV are received, the Transaction is expected to be completed on or about November 30, 2019.

Management of the Resulting Issuer

At closing of the Transaction, all of the existing directors and officers of Savanna will resign and the board of directors of the Resulting Issuer shall be composed of a minimum five (5) and a maximum of ten (10) directors.

The relevant professional experience of the currently proposed directors and officers of the Resulting Issuer is set out below:

Alejandro Jiménez Ramírez

Director

Alejandro Jiménez Ramírez has over 15 years of experience in corporate affairs providing advice to various companies relating to corporate law, environmental regulation, social responsibility, government engagement, communications, and sustainability matters. Mr. Ramirez is currently a Partner and Director at Aventtus, a consulting firm engaged in the Cannabis and Renewable Energy sectors. He concurrently serves as a Partner at Qvartz Capital Partners, an entity offering financial solutions and business development services for businesses in the resource, cannabis and renewable energy industries. Mr. Ramírez holds a law degree (J.D) and LL.M from the Universidad de los Andes (Colombia) and a Master of Business Administration (MBA) from Georgetown University – McDonough School of Business.

Alfredo Morales

Director

Alfredo Morales has 30 years of experience working in the “Fast Consumer Goods Sector” in Latin America serving companies such as Indega, Colgate Palmolive and the Energizer Battery Company. He currently serves as the President of Henkel KGAA (“ Henkel ”) for the Andean Region and as Vice President of the Henkel’s Beauty Retail business for Latin America. Working with Henkel, Mr. Morales has led the acquisition of several brands in Latin America. He is also the founder and owner of Iverpack, a company that designs packaging for flowers destined for export. Mr. Morales is currently a board member of a leading Colombian insurance company, Seguros Colmena, and the German-Colombian Chamber of Commerce. Mr. Morales has professional experience in sales development, marketing, trade marketing, general management supply chain management throughout Latin America, including areas of R&D, purchasing, and pack development. He holds a chemical engineering degree from Universidad Del Valle in Cali Colombia and an MBA and Master of Management from Tulane University in New Orleans, USA.

Juan José Martinez

Director

Juan José Martinez is an industrial engineer and holds a Master of Finance degree from the Universidad de los Andes (Colombia). He is currently acting as a Vice President in the “Fuels” sector for Primax Colombia. Mr. Martinez developed oil and gas industry experience over the past 20 years while working for ExxonMobil in the areas of downstream global marketing, retail and commercial businesses and strategic planning. During his time at ExxonMobil, Mr. Martinez worked on assignments in Argentina, Brazil, the United States and Colombia. He also has 5 years of experience in the flower industry, growing and exporting Colombian flowers for Magna Flowers where he assisted in the exportation of roses from Colombia to markets in the United States, Canada, Russia and Argentina.

Varianz and Savanna are currently seeking additional candidates for directors. More details of the number and identity of such directors will be disclosed in a further news release as it becomes available.

Management Services Agreement

Upon completion of the Transaction, the Resulting Issuer and an affiliate of Savanna (the “ Savanna Consultant ”) shall enter into a management services agreement (the “ Management Services Agreement ”) for a renewable term of one (1) year, whereby the Savanna Consultant will provide regulatory support services to the Resulting Issuer, including but not limited to, ensuring the completion of accurate and timely financial reporting, regulatory filings and all other TSXV and Canadian disclosure requirements. The Resulting Issuer will pay a fee to the Savanna Consultant for services provided under the Management Services Agreement, the amount of which shall be agreed to by Varianz and Savanna prior to the completion of the Transaction.

Engagement of WD Capital

Pursuant to a letter agreement dated August 30, 2019 (the “ Engagement Letter ”) WD Capital Markets Inc. (“ WD Capital ”) will provide certain advisory services to Varianz in connection with but not limited to: (a) general business and financial advice; and (b) financial advice in connection with the Transaction. Pursuant to the Engagement Letter the parties agreed that WD Capital will be paid a fee for services rendered thereunder equal to 3% of the imputed value of the Resulting Issuer on a pre-completion of the Transaction basis, payable in equity of the Resulting Issuer upon completion of the Transaction.   

BACKGROUND ON VARIANZ CORP. AND ITS SUBSIDIARIES

Varianz Corp.

Varianz is a Colombia-based privately held corporation existing under the laws of the Province of Ontario. Varianz Bio Lab S.A.S (“ Varianz Bio Lab ”), a wholly-owned subsidiary of Varianz (Varianz Bio Lab and Varianz Corp. are collectively referred to hereinafter as “ Varianz ”), is a biotechnology company focused on the medicinal cannabis industry, with headquarters in Bogotá, Colombia. Varianz intends to establish a vertically integrated operation to control a broad-scope value chain process from planting to processing cannabis, and ultimately producing high-quality medical cannabis oil extracts and other derivative products with rich CBD content.

Varianz Bio Lab has obtained from the Colombian Ministry of Justice and the Colombian Agricultural Institute, as applicable, licenses that:

  1. recognize Varianz Bio Lab as a cannabis seed producer in Colombia;
  2. allow Varianz Bio Lab to trade cannabis seeds; and
  3. allow Varianz Bio Lab to harvest non-psychoactive cannabis for: (i) seed production for crops; (ii) production of non-psychoactive cannabis derivatives (including sowing, transformation and disposition); (iii) industrial sale of non-psychoactive cannabis derivatives (excluding third party disposition and storage); and (iv) scientific disposition of non-psychoactive cannabis derivatives (excluding third party disposition and storage).

Varianz Bio Lab has also applied, and is awaiting approval, for a transformation license, which will allow Varianz Bio Lab to manufacture, produce, commercialize and export psychoactive and non-psychoactive cannabis derivatives for national, international and research purposes (the “ Transformation License ”). The Transformation License is a pre-requisite to Varianz Bio Lab receiving its Psychoactive Crop License (as defined below).

As of the date hereof, Varianz Bio Lab has received conditional approval of a psychoactive crop license that will allow Varianz Bio Lab to harvest psychoactive cannabis for: (a) seed production for crops; (b) production of psychoactive cannabis derivatives (including sowing, production of clones, storage, trading, distribution, exportation and final sale to third parties); (c) industrial sale; and (d) scientific disposition (the “ Psychoactive Crop License ”). Varianz Bio Lab anticipates that it will receive the Psychoactive Crop License and the Transformation License in September of 2019.

Relevant unaudited financial information for Varianz Bio Lab is summarized below:

AS AT DECEMBER 31, 2018*

Assets  
 Current  
  Cash and cash equivalents 1,632.03  
  Trade debtors and other payables 16,945.00  
Total current assets 18,577.07  
Non-current  
Property, plant and equipment 6,120.28  
Intangibles (Licences) 44,358.94  
Total non-current assets 50,468.41  
Total assets 69,050.65  
   
Liabilities  
Trade and other payables 80,716.05  
Total current liabilities   80,716.05  
   
Total non-current liabilities 0  
Total liabilities 80,716.05  
   
Equity  
Share Capital 1,631.72  
Income for the period (13,306.30 )
Total equity ( 11,674.42 )
Total liabilities and equity 69,050.65  

* Converted to Canadian Dollars from Colombian Pesos using exchange rate of COP 2456.81259 to CDN $1.00 effective on July 8, 2019.

About Savanna

Savanna is a Capital Pool Company (as defined in the policies of the Exchange) listed on the Exchange. Savanna has no material liabilities, approximately $150,000 in cash, 4,600,000 common shares and 443,200 options (the “ Savanna Options ”) issued and outstanding.

Further Information

For further information regarding the proposed Transaction, please contact:

Savanna Capital Corp. Kenny Choi Tel: (416) 861-2262 E-mail: Kenny.choi@fmresources.ca  

Varianz Corp. Alejandro Jimenez Tel: (+57) 314 220-5410 Email: IR@varianz.co

Certain statements in this release are forward-looking. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, as well as other factors beyond the Company's control. The Company does not undertake to update any forward looking information, except in accordance with applicable securities laws.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Boston STEM Expo Sparks Young Minds in Engineering

Updated Category News Views 286

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 188

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 206

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 21

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 105

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 271

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 98

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 61

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

Updated Category News Views 630

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 337

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights on 74Software's Voting Rights and Share Capital Details

Updated Category News Views 182

Understanding Voting Rights and Share Capital of 74Software In a recent communication, 74Software shared vital information regarding its voting rights and total share capital. As a company with a rich background in enterprise software, they remain committed to transparency with their shareholders. Highlights of Total Shares As of August 31, 2025, the total number of...

Continue Reading
Tenon Medical Earnings Report: Insights and Predictions Ahead

Updated Category News Views 125

Insights into Tenon Medical's Upcoming Earnings As the market anticipates the upcoming earnings release from Tenon Medical Inc (NASDAQ: TNON), investors are eager to understand what the future holds for the company. While the earnings date is set, the focus is largely on the earnings per share (EPS) forecasted at $-0.47. This brings both concern and hope as stakeholders...

Continue Reading
Cahill's New Counsel James Mandolfo Strengthens Investigations Team

Updated Category News Views 95

Cahill's New Counsel James Mandolfo Strengthens Investigations Team Cahill Gordon & Reindel LLP, a prestigious law firm known for its expertise and long-standing reputation in the legal field, has recently added James Mandolfo to its team. As part of the Congressional Investigations and White Collar Defense & Investigations practices, James brings a wealth of knowledge...

Continue Reading
Capstone Infrastructure Unveils Landmark Wind Projects with Partners

Updated Category News Views 311

Capstone Infrastructure's New Renewable Energy Initiatives Toronto, Ontario — Capstone Infrastructure Corporation (TSX: CSE.PR.A) is excited to share its involvement in three critical wind energy projects in collaboration with Indigenous partners. These projects highlight the Corporation's commitment to sustainable energy solutions and community empowerment....

Continue Reading
Investigation Raises Questions for Encompass Health Investors

Updated Category News Views 211

Investigation into Encompass Health Corporation Pomerantz LLP is currently conducting an investigation on behalf of investors in Encompass Health Corporation (NYSE: EHC). This investigation aims to uncover whether there have been any incidents of securities fraud or other unlawful business practices involving the company and its executives. Allegations of Unlawful...

Continue Reading